Theriva Biologics (NYSEAMERICAN:TOVX) Trading Up 0.7% – Should You Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) traded up 0.7% during trading on Monday . The stock traded as high as $1.46 and last traded at $1.43. 41,449 shares were traded during mid-day trading, a decline of 84% from the average session volume of 251,771 shares. The stock had previously closed at $1.42.

Analyst Upgrades and Downgrades

Separately, Maxim Group reduced their target price on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Theriva Biologics Trading Up 0.7 %

The stock has a market capitalization of $3.98 million, a PE ratio of -0.04 and a beta of 1.22.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($6.81) EPS for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP purchased a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent SEC filing. Institutional investors own 6.17% of the company’s stock.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.